Home » Topics » Regulatory » EMA

EMA
RSS

Protalix BioTherapeutics initiates global phase III study of PRX-102 in Fabry disease

June 7, 2016

Kite Pharma granted access to European PRIME initiative for KTE-C19 in DLBCL

June 2, 2016

Can-Fite reaches agreement with EMA for piclidenoson phase III trial

June 2, 2016

CCX-168 receives EMA PRIME designation for AAV

June 2, 2016

QR-110 from ProQR Therapeutics receives U.S. and E.U. orphan drug designations

June 2, 2016

EMA committee supports expanding approval of Tysabri

June 1, 2016

BioMarin withdraws Kyndrisa MAA, discontinues development of follow-on products

June 1, 2016

Simponi receives positive opinion in Europe for treatment of pJIA

May 31, 2016

EMA committee hands down positive opinion to extend Kyprolis indication

May 30, 2016

Saxagliptin/dapagliflozin receives positive opinion in E.U.

May 30, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 15, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Rethinking anorexia: A disorder of mind and metabolism
BioWorld Science
Anorexia nervosa (AN) is a complex and severe eating disorder that has long been considered a psychiatric condition driven by distorted body image and maladaptive...